Estrogen receptor-α and C-ERBB-4 expression in breast carcinomas

• Published in: Virchows Archiv : an international journal of pathology 2001-07, Vol.439 (1), p.62-69
• Main Authors: ZHENHE SUO, BERNER, Heidi Siri, RISBERG, Björn, KARLSSON, Mats G, NESLAND, Jahn M
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Dissection; DNA Primers - chemistry; Estrogen Receptor alpha; Female; Fluorescent Antibody Technique, Indirect; Gynecology. Andrology. Obstetrics; Humans; Mammary gland diseases; Medical sciences; Micromanipulation; Receptor, Epidermal Growth Factor - metabolism; Receptor, ErbB-4; Receptors, Estrogen - metabolism; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger - metabolism; RNA, Neoplasm - analysis; Tumor Cells, Cultured; Tumors
• ISSN: 0945-6317; 1432-2307
• DOI: 10.1007/s004280000392

The presence of estrogen receptors (ERs) in breast carcinomas is important for clinical response to endocrine therapy. However, the cellular mechanisms following ER activation are not fully understood. It has been indicated that expression of the ER is associated with the expression of c-erbB-4. To address this question, 103 breast carcinoma samples were studied using reverse transcriptase polymerase chain reaction (RT-PCR) analysis after application of a microselection method for RNA isolation. Total RNA for RT-PCR was isolated from 20-microm-thick frozen sections, which were made from microselected areas. Paraffin blocks from 98 of these 103 tumors were also immunohistochemically examined. Significant associations between ER-alpha and c-erbB-4 mRNA and protein expressions were found in the present study with both methods. One-fourth of the tumors did not express ER-alpha (22%, 24%, and 26% with chemical binding, immunohistochemistry, and RT-PCR, respectively). About one-half of the ER-alpha negative tumors did not express c-erbB-4 on both mRNA and protein levels (48% with RT-PCR and 46% with immunohistochemistry, P=0.001 for both methods). The endocrine therapy responsive breast cancer cell lines MCF-7 and T47-D were positive for both ER-alpha and c-erbB-4 expression, while the endocrine therapy nonresponsive breast cancer cell lines MDA-MD-231 and SK-BR-3 were not. Thus, we confirm the association between the expression of ER-alpha and c-erbB-4 mRNA and protein in breast carcinomas, indicating a role for c-erbB-4 in estrogen signal transduction.